Biomarkers for the diagnosis of Alzheimer's disease in clinical practice: an Italian intersocietal roadmap

G.B. Frisoni; D. Perani; S. Bastianello; G. Bernardi; C. Porteri; M. Boccardi; S.F. Cappa; M. Trabucchi; A. Padovani

doi:10.1016/j.neurobiolaging.2016.02.033

Biomarkers for the diagnosis of Alzheimer's disease in clinical practice: an Italian intersocietal roadmap

G.B. Frisoni, D. Perani, S. Bastianello, G. Bernardi, C. Porteri, M. Boccardi, S.F. Cappa, M. Trabucchi, A. Padovani

Centro San Giovanni di Dio - Fatebenefratelli

Research output: Contribution to journal › Article › peer-review

Abstract

Biomarkers of brain amyloidosis and neurodegeneration/synaptic dysfunction are featured in recent diagnostic criteria for Alzheimer's disease. Several gaps in our knowledge, however, need to be filled before they can be adopted clinically. The aim of this article is to describe a roadmap, developed by a multidisciplinary task force, to rationally implement biomarkers for Italian Memory Clinics. This roadmap is based on a framework comprising 5 sequential phases: identification of leads for potentially useful biomarkers; development of clinical assays for clinical disease; evaluation of detection of early stages; definition of operating characteristics in relevant populations; and estimation of reducing disease-associated mortality, morbidity, and disability. The roadmap was devised by identifying current evidence of validity, still missing evidence, and action needed to collect this missing evidence. With appropriate adaptation to local, country-specific circumstances, the roadmap can be translated to other countries. © 2016 Elsevier Inc.

Original language	English
Pages (from-to)	119-131
Number of pages	13
Journal	Neurobiology of Aging
Volume	52
DOIs	https://doi.org/10.1016/j.neurobiolaging.2016.02.033
Publication status	Published - 2017

Keywords

Alzheimer
Biomarkers
Diagnosis
Validation
biological marker
tau protein
amyloid beta protein
amyloid beta-protein (1-42)
peptide fragment
Alzheimer disease
Article
brain atrophy
cerebrospinal fluid analysis
clinical practice
comorbidity
cost benefit analysis
diagnostic accuracy
differential diagnosis
disability
disease association
hippocampus
human
ligand binding
mortality
neuropsychological test
prognosis
protein expression
cerebrospinal fluid
diagnostic imaging
diffusion weighted imaging
Italy
positron emission tomography
single photon emission computed tomography
Alzheimer Disease
Amyloid beta-Peptides
Diffusion Magnetic Resonance Imaging
Humans
Peptide Fragments
Positron-Emission Tomography
tau Proteins
Tomography, Emission-Computed, Single-Photon

Access to Document

10.1016/j.neurobiolaging.2016.02.033

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85015404117&doi=10.1016%2fj.neurobiolaging.2016.02.033&partnerID=40&md5=be20147dd02d748af22e79f261fd1e03

Fingerprint Dive into the research topics of 'Biomarkers for the diagnosis of Alzheimer's disease in clinical practice: an Italian intersocietal roadmap'. Together they form a unique fingerprint.

Cite this

@article{69ce8d4f3c13423fa7af803e4cc14abd,

title = "Biomarkers for the diagnosis of Alzheimer's disease in clinical practice: an Italian intersocietal roadmap",

abstract = "Biomarkers of brain amyloidosis and neurodegeneration/synaptic dysfunction are featured in recent diagnostic criteria for Alzheimer's disease. Several gaps in our knowledge, however, need to be filled before they can be adopted clinically. The aim of this article is to describe a roadmap, developed by a multidisciplinary task force, to rationally implement biomarkers for Italian Memory Clinics. This roadmap is based on a framework comprising 5 sequential phases: identification of leads for potentially useful biomarkers; development of clinical assays for clinical disease; evaluation of detection of early stages; definition of operating characteristics in relevant populations; and estimation of reducing disease-associated mortality, morbidity, and disability. The roadmap was devised by identifying current evidence of validity, still missing evidence, and action needed to collect this missing evidence. With appropriate adaptation to local, country-specific circumstances, the roadmap can be translated to other countries. {\textcopyright} 2016 Elsevier Inc.",

keywords = "Alzheimer, Biomarkers, Diagnosis, Validation, biological marker, tau protein, amyloid beta protein, amyloid beta-protein (1-42), peptide fragment, Alzheimer disease, Article, brain atrophy, cerebrospinal fluid analysis, clinical practice, comorbidity, cost benefit analysis, diagnostic accuracy, differential diagnosis, disability, disease association, hippocampus, human, ligand binding, mortality, neuropsychological test, prognosis, protein expression, cerebrospinal fluid, diagnostic imaging, diffusion weighted imaging, Italy, positron emission tomography, single photon emission computed tomography, Alzheimer Disease, Amyloid beta-Peptides, Diffusion Magnetic Resonance Imaging, Humans, Peptide Fragments, Positron-Emission Tomography, tau Proteins, Tomography, Emission-Computed, Single-Photon",

author = "G.B. Frisoni and D. Perani and S. Bastianello and G. Bernardi and C. Porteri and M. Boccardi and S.F. Cappa and M. Trabucchi and A. Padovani",

note = "Cited By :13 Export Date: 26 February 2018 CODEN: NEAGD Correspondence Address: Frisoni, G.B.; IRCCS Fatebenefratelli, via Pilastroni 4, Italy; email: giovanni.frisoni@gmail.com",

year = "2017",

doi = "10.1016/j.neurobiolaging.2016.02.033",

language = "English",

volume = "52",

pages = "119--131",

journal = "Neurobiology of Aging",

issn = "0197-4580",

publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Biomarkers for the diagnosis of Alzheimer's disease in clinical practice: an Italian intersocietal roadmap

AU - Frisoni, G.B.

AU - Perani, D.

AU - Bastianello, S.

AU - Bernardi, G.

AU - Porteri, C.

AU - Boccardi, M.

AU - Cappa, S.F.

AU - Trabucchi, M.

AU - Padovani, A.

N1 - Cited By :13 Export Date: 26 February 2018 CODEN: NEAGD Correspondence Address: Frisoni, G.B.; IRCCS Fatebenefratelli, via Pilastroni 4, Italy; email: giovanni.frisoni@gmail.com

PY - 2017

Y1 - 2017

N2 - Biomarkers of brain amyloidosis and neurodegeneration/synaptic dysfunction are featured in recent diagnostic criteria for Alzheimer's disease. Several gaps in our knowledge, however, need to be filled before they can be adopted clinically. The aim of this article is to describe a roadmap, developed by a multidisciplinary task force, to rationally implement biomarkers for Italian Memory Clinics. This roadmap is based on a framework comprising 5 sequential phases: identification of leads for potentially useful biomarkers; development of clinical assays for clinical disease; evaluation of detection of early stages; definition of operating characteristics in relevant populations; and estimation of reducing disease-associated mortality, morbidity, and disability. The roadmap was devised by identifying current evidence of validity, still missing evidence, and action needed to collect this missing evidence. With appropriate adaptation to local, country-specific circumstances, the roadmap can be translated to other countries. © 2016 Elsevier Inc.

AB - Biomarkers of brain amyloidosis and neurodegeneration/synaptic dysfunction are featured in recent diagnostic criteria for Alzheimer's disease. Several gaps in our knowledge, however, need to be filled before they can be adopted clinically. The aim of this article is to describe a roadmap, developed by a multidisciplinary task force, to rationally implement biomarkers for Italian Memory Clinics. This roadmap is based on a framework comprising 5 sequential phases: identification of leads for potentially useful biomarkers; development of clinical assays for clinical disease; evaluation of detection of early stages; definition of operating characteristics in relevant populations; and estimation of reducing disease-associated mortality, morbidity, and disability. The roadmap was devised by identifying current evidence of validity, still missing evidence, and action needed to collect this missing evidence. With appropriate adaptation to local, country-specific circumstances, the roadmap can be translated to other countries. © 2016 Elsevier Inc.

KW - Alzheimer

KW - Biomarkers

KW - Diagnosis

KW - Validation

KW - biological marker

KW - tau protein

KW - amyloid beta protein

KW - amyloid beta-protein (1-42)

KW - peptide fragment

KW - Alzheimer disease

KW - Article

KW - brain atrophy

KW - cerebrospinal fluid analysis

KW - clinical practice

KW - comorbidity

KW - cost benefit analysis

KW - diagnostic accuracy

KW - differential diagnosis

KW - disability

KW - disease association

KW - hippocampus

KW - human

KW - ligand binding

KW - mortality

KW - neuropsychological test

KW - prognosis

KW - protein expression

KW - cerebrospinal fluid

KW - diagnostic imaging

KW - diffusion weighted imaging

KW - Italy

KW - positron emission tomography

KW - single photon emission computed tomography

KW - Alzheimer Disease

KW - Amyloid beta-Peptides

KW - Diffusion Magnetic Resonance Imaging

KW - Humans

KW - Peptide Fragments

KW - Positron-Emission Tomography

KW - tau Proteins

KW - Tomography, Emission-Computed, Single-Photon

U2 - 10.1016/j.neurobiolaging.2016.02.033

DO - 10.1016/j.neurobiolaging.2016.02.033

M3 - Article

VL - 52

SP - 119

EP - 131

JO - Neurobiology of Aging

JF - Neurobiology of Aging

SN - 0197-4580

ER -